Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer

Eun Ji Nam, Jae Wook Kim, Jae Hoon Kim, Sunghoon Kim, Sang Wun Kim, Si Young Jang, Dae Woo Lee, Yong Wook Jung, Young Tae Kim

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Objective: This study was performed to determine the safety and efficacy of belotecan, a new camptothecin analogue and potent topoisomerase I inhibitor, with and without platinum in patients with recurrent ovarian cancer. Methods: Fifty-three patients with recurrent or persistent ovarian cancer were enrolled between March 2005 and March 2008. Eligible patients received 0.5 mg/m of intravenous (IV) belotecan on days 1 to 5, every 3 weeks belotecan monotherapy (B) or 50 mg/m of IV cisplatin on day 1 plus 0.3 mg/m of IV belotecan on days 1 to 5, every 3 weeks (belotecan plus cisplatin combination therapy [BP]). Results: Of the 53 treated patients, 34 received BP and 19 received B. Thirty-four patients had platinum-sensitive (PS) disease and 19 had platinum-resistant disease. The overall response of the 53 patients was 37.7% (20/53). According to regimen, the response rate in the BP group was 47.1% (16/34) and that of the B group was 21.1% (4/19). BP had better response (66.7%, 14/21) than B (15.4%, 2/13) for PS disease (P = 0.004), but it was not superior in terms of progression-free survival (BP, 6 month; B, 7 months). Grade 3 or 4 toxicity was less common in B than in BP. Conclusion: Both BP and B seems to be effective and safe regimens for patients with PS or platinum-resistant recurrent ovarian cancer. These results warrant further prospective randomized trials. Both BP and B seems to be effective and safe regimens for patients with PS or platinum-resistant recurrent ovarian cancer.

Original languageEnglish
Pages (from-to)233-237
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume33
Issue number3
DOIs
Publication statusPublished - 2010 Jun 1

Fingerprint

Platinum
Ovarian Neoplasms
Cisplatin
Topoisomerase I Inhibitors
Camptothecin
belotecan
Disease-Free Survival
Safety

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Nam, Eun Ji ; Kim, Jae Wook ; Kim, Jae Hoon ; Kim, Sunghoon ; Kim, Sang Wun ; Jang, Si Young ; Lee, Dae Woo ; Jung, Yong Wook ; Kim, Young Tae. / Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2010 ; Vol. 33, No. 3. pp. 233-237.
@article{a8fa7ce1baaa4c50b85954674c036899,
title = "Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer",
abstract = "Objective: This study was performed to determine the safety and efficacy of belotecan, a new camptothecin analogue and potent topoisomerase I inhibitor, with and without platinum in patients with recurrent ovarian cancer. Methods: Fifty-three patients with recurrent or persistent ovarian cancer were enrolled between March 2005 and March 2008. Eligible patients received 0.5 mg/m of intravenous (IV) belotecan on days 1 to 5, every 3 weeks belotecan monotherapy (B) or 50 mg/m of IV cisplatin on day 1 plus 0.3 mg/m of IV belotecan on days 1 to 5, every 3 weeks (belotecan plus cisplatin combination therapy [BP]). Results: Of the 53 treated patients, 34 received BP and 19 received B. Thirty-four patients had platinum-sensitive (PS) disease and 19 had platinum-resistant disease. The overall response of the 53 patients was 37.7{\%} (20/53). According to regimen, the response rate in the BP group was 47.1{\%} (16/34) and that of the B group was 21.1{\%} (4/19). BP had better response (66.7{\%}, 14/21) than B (15.4{\%}, 2/13) for PS disease (P = 0.004), but it was not superior in terms of progression-free survival (BP, 6 month; B, 7 months). Grade 3 or 4 toxicity was less common in B than in BP. Conclusion: Both BP and B seems to be effective and safe regimens for patients with PS or platinum-resistant recurrent ovarian cancer. These results warrant further prospective randomized trials. Both BP and B seems to be effective and safe regimens for patients with PS or platinum-resistant recurrent ovarian cancer.",
author = "Nam, {Eun Ji} and Kim, {Jae Wook} and Kim, {Jae Hoon} and Sunghoon Kim and Kim, {Sang Wun} and Jang, {Si Young} and Lee, {Dae Woo} and Jung, {Yong Wook} and Kim, {Young Tae}",
year = "2010",
month = "6",
day = "1",
doi = "10.1097/COC.0b013e3181a650bc",
language = "English",
volume = "33",
pages = "233--237",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer. / Nam, Eun Ji; Kim, Jae Wook; Kim, Jae Hoon; Kim, Sunghoon; Kim, Sang Wun; Jang, Si Young; Lee, Dae Woo; Jung, Yong Wook; Kim, Young Tae.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 33, No. 3, 01.06.2010, p. 233-237.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy and toxicity of belotecan with and without cisplatin in patients with recurrent ovarian cancer

AU - Nam, Eun Ji

AU - Kim, Jae Wook

AU - Kim, Jae Hoon

AU - Kim, Sunghoon

AU - Kim, Sang Wun

AU - Jang, Si Young

AU - Lee, Dae Woo

AU - Jung, Yong Wook

AU - Kim, Young Tae

PY - 2010/6/1

Y1 - 2010/6/1

N2 - Objective: This study was performed to determine the safety and efficacy of belotecan, a new camptothecin analogue and potent topoisomerase I inhibitor, with and without platinum in patients with recurrent ovarian cancer. Methods: Fifty-three patients with recurrent or persistent ovarian cancer were enrolled between March 2005 and March 2008. Eligible patients received 0.5 mg/m of intravenous (IV) belotecan on days 1 to 5, every 3 weeks belotecan monotherapy (B) or 50 mg/m of IV cisplatin on day 1 plus 0.3 mg/m of IV belotecan on days 1 to 5, every 3 weeks (belotecan plus cisplatin combination therapy [BP]). Results: Of the 53 treated patients, 34 received BP and 19 received B. Thirty-four patients had platinum-sensitive (PS) disease and 19 had platinum-resistant disease. The overall response of the 53 patients was 37.7% (20/53). According to regimen, the response rate in the BP group was 47.1% (16/34) and that of the B group was 21.1% (4/19). BP had better response (66.7%, 14/21) than B (15.4%, 2/13) for PS disease (P = 0.004), but it was not superior in terms of progression-free survival (BP, 6 month; B, 7 months). Grade 3 or 4 toxicity was less common in B than in BP. Conclusion: Both BP and B seems to be effective and safe regimens for patients with PS or platinum-resistant recurrent ovarian cancer. These results warrant further prospective randomized trials. Both BP and B seems to be effective and safe regimens for patients with PS or platinum-resistant recurrent ovarian cancer.

AB - Objective: This study was performed to determine the safety and efficacy of belotecan, a new camptothecin analogue and potent topoisomerase I inhibitor, with and without platinum in patients with recurrent ovarian cancer. Methods: Fifty-three patients with recurrent or persistent ovarian cancer were enrolled between March 2005 and March 2008. Eligible patients received 0.5 mg/m of intravenous (IV) belotecan on days 1 to 5, every 3 weeks belotecan monotherapy (B) or 50 mg/m of IV cisplatin on day 1 plus 0.3 mg/m of IV belotecan on days 1 to 5, every 3 weeks (belotecan plus cisplatin combination therapy [BP]). Results: Of the 53 treated patients, 34 received BP and 19 received B. Thirty-four patients had platinum-sensitive (PS) disease and 19 had platinum-resistant disease. The overall response of the 53 patients was 37.7% (20/53). According to regimen, the response rate in the BP group was 47.1% (16/34) and that of the B group was 21.1% (4/19). BP had better response (66.7%, 14/21) than B (15.4%, 2/13) for PS disease (P = 0.004), but it was not superior in terms of progression-free survival (BP, 6 month; B, 7 months). Grade 3 or 4 toxicity was less common in B than in BP. Conclusion: Both BP and B seems to be effective and safe regimens for patients with PS or platinum-resistant recurrent ovarian cancer. These results warrant further prospective randomized trials. Both BP and B seems to be effective and safe regimens for patients with PS or platinum-resistant recurrent ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=77953335343&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953335343&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3181a650bc

DO - 10.1097/COC.0b013e3181a650bc

M3 - Article

C2 - 19745693

AN - SCOPUS:77953335343

VL - 33

SP - 233

EP - 237

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -